BioNTech SE: Pfizer and BioNTech Initiate Rolling Submission

With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy of two 3 µg doses as part of a three-dose primary

Related Keywords

Germany , Finland , United States , Canada , Poland , United Kingdom , Spain , American , Sylke Maas , Albert Bourla , Ugur Sahin , Fosun Pharma , American Academy Of Pediatrics , Centers For Disease , Linkedin , Genentech , Twitter , Drug Administration , Bayer Animal Health , Exchange Commission , Pfizer , Pfizer Inc , European Union , European Medicines Agency , Facebook , Roche Group , Emergency Use Authorization , Chief Executive Officer , Marketing Authorization Holder , Emergency Use , Drug Administrations , Prescribing Information , Caregivers Fact , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , New Technologies , Private Securities Litigation Reform Act , Year Ended December , State Level Data , American Academy , Updated January , Disease Control , Biontech , Nitiate , Rolling , Submission , Emergency , Authorization , Their , Covid , Vaccine , Children , Months , Through , Tears , Following , Request , Rom ,